Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.13709 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2025. Verfasst von Yoshinori Hayashi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Medicine, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Neoplasms, Biomarkers, Tumor, MicroRNAs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr Miriam and Sheldon G. Adelson Medical Research Foundation, Martin and Pauline Collins Family (Ensign Foundation Los Angeles, CA, USA), Diane Feldman Donations.
Abstract (Originalsprache)
As cutting‐edge technologies applied for the study of body fluid molecular biomarkers are continuously evolving, clinical applications of these biomarkers improve. Diverse forms of circulating molecular biomarkers have been described, including cell‐free DNA (cfDNA), circulating tumor cells (CTCs), and cell‐free microRNAs (cfmiRs), although unresolved issues remain in their applicability, specificity, sensitivity, and reproducibility. Translational studies demonstrating the clinical utility and importance of cfmiRs in multiple cancers have significantly increased. This review aims to summarize the last 5 years of translational cancer research in the field of cfmiRs and their potential clinical applications to diagnosis, prognosis, and monitoring disease recurrence or treatment responses with a focus on solid tumors. PubMed was utilized for the literature search, following rigorous exclusion criteria for studies based on tumor types, patient sample size, and clinical applications. A total of 136 studies on cfmiRs in different solid tumors were identified and divided based on tumor types, organ sites, number of cfmiRs found, methodology, and types of biofluids analyzed. This comprehensive review emphasizes clinical applications of cfmiRs and summarizes underserved areas where more research and validations are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Molecular Medicine, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
- Department of Surgical Oncology, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
- Department of Urology and Urologic Oncology, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
- Department of Genome Sequencing Center, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
ORCID-Profile: Dave S B Hoon, Matias A Bustos
Förderung
- Dr Miriam and Sheldon G. Adelson Medical Research Foundation
- Martin and Pauline Collins Family (Ensign Foundation Los Angeles, CA, USA)
- Diane Feldman Donations
Zitieren
APA
Hayashi, Y., Millen, J. C., Ramos, R. I., Linehan, J. A., Wilson, T. G., Hoon, D. S. B., & Bustos, M. A. (2025). Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors. Molecular Oncology. https://doi.org/10.1002/1878-0261.13709
Vancouver
Hayashi Y, Millen JC, Ramos RI, Linehan JA, Wilson TG, Hoon DSB, et al. Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors. Molecular Oncology. 2025. doi:10.1002/1878-0261.13709
BibTeX
@article{Hayashi2025,
author = {Hayashi, Yoshinori and Millen, Janelle-Cheri and Ramos, Romela Irene and Linehan, Jennifer A and Wilson, Timothy G and Hoon, Dave S B and Bustos, Matias A},
title = {Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.13709}
}
EUVIMED